Sunshine Lake Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, production, and commercialization of drugs. The company develops small molecule drugs, biologics, and biosimilars, with a focus on therapeutic areas including infectious diseases, chronic diseases, and oncology. Its product portfolio includes approved medicines for influenza, hepatitis C, and diabetes, alongside a pipeline of candidates in various stages of clinical trials. The company operates integrated capabilities for drug discovery, manufacturing, and sales, utilizing AI-driven models to support its research processes. It serves markets in China, the United States, and Europe, and has established partnerships for the commercialization of specific drug candidates.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage hecpharm.com
Sector Healthcare IR page hecpharm.com/investor_relations.html
Tags
innovative drugs, biosimilars, generic drugs, infectious diseases, oncology, diabetes, ai drug discovery, cdmo services, small molecule drugs, biologics, Dongguan HEC Medicine, Dongguan HEC Biopharmaceutical, Guangdong HEC Biopharmaceutical, Shenzhen HEC Industrial, Guangdong HEC Technology Holding Co. Ltd., Yichang HEC Medicine, Dongguan HEC Research, Dongguan HEC Medical, HEC CJ Pharm, Guangzhou Yangzhiguang Trading Co. Ltd., Ruyuan Yao Autonomous County Taidong Pharmaceutical Co. Ltd., Yidu Tang Junyi Health Industry Development Co. Ltd., Yidu Tang Juntao Pharmaceutical Technology Co. Ltd., Dongguan HEC Gaoneng Medical Equipment Co. Ltd., Linzhi HEC Pharmaceutical Research, Dongguan HEC Industrial Development Co. Ltd., Yichang HEC Research, Guangdong Southern China Advanced Pharmaceutical Co. Ltd., Dongyang HEC Industrial Development Co. Ltd., Yidu HEC Industrial, HEC-SynAI, HEC169584, HEC88473, HECN30227, Olopatadine, Natanvir, Ecozibuvir, Fingolimod, Emtravirine, Ifeenikone, Azithromycin, Oseltamivir, Insulin, Glargine, Aspart, Aspart 30
Press page —

Metrics

Valuation  
Market cap HK$ 11.77B
Market cap (USD) $ 1.5B
P/E 59.02
PEG —
P/BV 3.36
P/S 2.08
P/OCF 8.66
P/FCF —
Dividend yield —
Turnover / mcap 0.13%
Returns  
ROE 6.2%
ROI 3.1%
ROIC 7.5%
Profit margin 5.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 105.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 41.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Revenue 4.815B 4.019B
Net profit 272.442M -207.434M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Sunshine Lake Pharma Co., Ltd. (ticker 6887), listed in Hong Kong.

ETFs Holding Sunshine Lake Pharma Co., Ltd.

ETF Weight in ETF Shares Market value As of
AVEE 0.11% 30,500 $ 141.867K Nov 16, 2026
AVEM 0.01% 725,105 $ 3.373M Nov 16, 2026
DFEM 0.01% 147,572 $ 711.839K Nov 12, 2026
DFSE 0.00% 3,532 $ 17.037K Nov 12, 2026
DFAX 0.00% 62,658 $ 302.241K Nov 12, 2026
DFAE 0.00% 39,669 $ 191.35K Nov 12, 2026
AVES 0.00% 10,218 $ 47.528K Nov 16, 2026
AVSE 0.00% 52 $ 241.87 Nov 16, 2026